Sanofi (SNY) has released an update. Sanofi reported a robust 15.7% growth in sales for Q3 2024, driven by strong performances in its vaccine and pharmaceutical segments, notably with Dupixent ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

PARIS (Reuters) -French unions have called on workers at Sanofi to strike from Thursday to protest a planned sale of the ...

David Risinger has given his Buy rating due to a combination of factors that highlight Sanofi’s strategic maneuvers and financial prospects. One key reason is the valuation of Opella at €16 ...

Sanofi SAN-1.01%decrease; red down pointing triangle moved ahead with a plan to sell a controlling stake in its consumer-healthcare unit Opella to Clayton Dubilier & Rice, entering exclusive talks ...

Sanofi SAN-0.92%decrease; red down pointing triangle is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company ...

Oct 25 (Reuters) - French drug maker Sanofi (SASY.PA), opens new tab on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than ...

PAI Partners has submitted an improved offer for Sanofi’s consumer health business, according to people familiar with the matter, an unexpected twist in one of the biggest deals in Europe this year.

PARIS (Reuters) -Sanofi on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R), French ...

Sanofi pitched today’s announcement in the context of its move last month to pay Orano Med and its partner RadioMedix 100 million euros upfront and commit up to 220 million euros in sales ...

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.